Clinical Trials Browser

Phase 3 × fezolinetant × 90 days × Clear all

NCT06440967 2026-04-06

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

Phase 3 Active not recruiting

Hot Flashes